Clinical Trials Browser

Active not recruiting × idelalisib × 90 days × Clear all

NCT02787369 2026-05-19

ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL

Phase 1 Active not recruiting

LymphoidOther hematologic neoplasm

Leukemia, Leukemia, B-Cell

NCT02970318 2026-05-11

A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

Phase 3 Active not recruiting

310 enrolled 18 charts 1 FDA

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04666038 2026-04-24

BRUIN CLL-321

Phase 3 Active not recruiting

238 enrolled 17 charts 1 FDA

LymphoidOther hematologic neoplasm

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell